 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...678910111213141516...2223» |
- ||||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial completion, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Dec 8, 2020
P3, N=529, Completed, Sponsor: Immunomedics, Inc.
Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Dec 7, 2020
P2, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial completion date: Aug 2021 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: EMBRACE: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (clinicaltrials.gov) - Dec 4, 2020
P3, N=200, Suspended, Sponsor: Academic and Community Cancer Research United
Trial completion date: Aug 2021 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023 Trial primary completion date: Aug 2021 --> Jun 2020
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Dec 2, 2020
P2, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2021 --> Jun 2020 Trial primary completion date: Aug 2020 --> Aug 2021 | Trial completion date: Aug 2020 --> Aug 2021
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed, Enrollment change, Metastases: Loreline Study: Characterization of Long Responders Under Eribuline (clinicaltrials.gov) - Nov 30, 2020
P=N/A, N=97, Active, not recruiting, Sponsor: Centre Jean Perrin
Trial primary completion date: Aug 2020 --> Aug 2021 | Trial completion date: Aug 2020 --> Aug 2021 Recruiting --> Active, not recruiting | N=200 --> 97
- ||||| balixafortide (POL 6326) / Spexis
Enrollment closed, Combination therapy, Metastases: FORTRESS: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 30, 2020
P3, N=384, Active, not recruiting, Sponsor: Polyphor Ltd.
Recruiting --> Active, not recruiting | N=200 --> 97 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, Metastases: Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) (clinicaltrials.gov) - Nov 25, 2020
P3, N=622, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| ipatasertib (RG7440) / Roche
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: PATHFINDER: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Nov 24, 2020
P2a, N=54, Recruiting, Sponsor: MedSIR
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Jul 2021 --> Mar 2022
- |||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment open: EVER-132-002: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Nov 24, 2020
P3, N=330, Recruiting, Sponsor: Everest Medicines
Not yet recruiting --> Recruiting | Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Jul 2021 --> Mar 2022 Not yet recruiting --> Recruiting
- |||||||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
New P3 trial: EVER-132-002: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Nov 22, 2020
P3, N=330, Not yet recruiting, Sponsor: Everest Medicines
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) (clinicaltrials.gov) - Nov 19, 2020
P2, N=45, Recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 (clinicaltrials.gov) - Nov 13, 2020
P2, N=54, Completed, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Active, not recruiting --> Completed | N=162 --> 54
- | Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer (clinicaltrials.gov) - Nov 11, 2020
P2, N=40, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Halaven (eribulin mesylate) / Eisai
Trial initiation date: SWOG S1937: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (clinicaltrials.gov) - Nov 6, 2020
P3, N=465, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=162 --> 54 Initiation date: May 2021 --> Dec 2020
- ||| Talzenna (talazoparib) / Pfizer
Trial completion date, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Nov 4, 2020
P3, N=431, Active, not recruiting, Sponsor: Pfizer
Initiation date: May 2021 --> Dec 2020 Trial completion date: Sep 2020 --> Dec 2020
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date: A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Oct 27, 2020
P1/2, N=21, Completed, Sponsor: University of Colorado, Denver
Trial completion date: Sep 2020 --> Dec 2020 Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Jan 2020
- | Kineret (anakinra) / SOBI
Trial completion, Enrollment change: Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients (clinicaltrials.gov) - Oct 23, 2020
P1, N=10, Completed, Sponsor: Baylor Research Institute
Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Jan 2020 Recruiting --> Completed | N=20 --> 10
- | Halaven (eribulin mesylate) / Eisai
New P3 trial: SWOG S1937: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (clinicaltrials.gov) - Oct 7, 2020
P3, N=465, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Sep 23, 2020
P3, N=436, Active, not recruiting, Sponsor: Byondis B.V.
Recruiting --> Completed | N=20 --> 10 Recruiting --> Active, not recruiting | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: Jul 2020 --> Jul 2021
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: EMBRACE: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (clinicaltrials.gov) - Sep 17, 2020
P3, N=200, Suspended, Sponsor: Academic and Community Cancer Research United
Recruiting --> Active, not recruiting | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: Jul 2020 --> Jul 2021 Trial primary completion date: Aug 2020 --> Aug 2021
- | Halaven (eribulin mesylate) / Eisai
New trial, Metastases: Eribulin in mTNBC Patients (clinicaltrials.gov) - Sep 8, 2020
P, N=100, Active, not recruiting, Sponsor: Fudan University
- | Trial completion date, Trial primary completion date, PD(L)-1 Biomarker: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 3, 2020
P1, N=24, Recruiting, Sponsor: Presage Biosciences
Trial primary completion date: Aug 2020 --> Aug 2021 Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020
- | Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
Enrollment open, PD(L)-1 Biomarker, IO biomarker: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Sep 2, 2020
P2, N=78, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020 Suspended --> Recruiting
- ||||| Onzeald (etirinotecan pegol) / Nektar Therap
Trial completion, Trial completion date, Metastases: ATTAIN: A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (clinicaltrials.gov) - Aug 24, 2020
P3, N=178, Completed, Sponsor: Nektar Therapeutics
Suspended --> Recruiting Active, not recruiting --> Completed | Trial completion date: Mar 2021 --> Jul 2020
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - Aug 19, 2020
P1b, N=16, Recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed | Trial completion date: Mar 2021 --> Jul 2020 Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Feb 2020 --> Feb 2022
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Aug 17, 2020
P2, N=160, Not yet recruiting, Sponsor: Fudan University
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Enrollment change, Trial completion date: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Aug 14, 2020
P1b/2, N=258, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Feb 2020 --> Feb 2022 Completed --> Active, not recruiting | N=167 --> 258 | Trial completion date: Jul 2019 --> Feb 2021
- ||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial completion date, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Aug 13, 2020
P3, N=529, Active, not recruiting, Sponsor: Immunomedics, Inc.
Completed --> Active, not recruiting | N=167 --> 258 | Trial completion date: Jul 2019 --> Feb 2021 Trial completion date: Jul 2020 --> Oct 2020
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Evaluate Eribulin ORA in Subjects With Solid Tumors (clinicaltrials.gov) - Aug 12, 2020
P1, N=50, Recruiting, Sponsor: Athenex, Inc.
Trial completion date: Jul 2020 --> Oct 2020 Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
- | Halaven (eribulin mesylate) / Eisai
Trial completion: Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate (clinicaltrials.gov) - Aug 8, 2020
P2, N=9, Completed, Sponsor: Case Comprehensive Cancer Center
Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Apr 2020 --> Apr 2021 Active, not recruiting --> Completed
- || Halaven (eribulin mesylate) / Eisai, Imfinzi (durvalumab) / AstraZeneca
Trial completion, Trial completion date: Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer (clinicaltrials.gov) - Aug 8, 2020
P1, N=9, Completed, Sponsor: Amy Tiersten
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Feb 2021 --> Feb 2020
- | Halaven (eribulin mesylate) / Eisai
New P2 trial: EMBRAVE-001: Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Aug 6, 2020
P2, N=100, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: Loreline Study: Characterization of Long Responders Under Eribuline (clinicaltrials.gov) - Jul 14, 2020
P=N/A, N=200, Recruiting, Sponsor: Centre Jean Perrin
Active, not recruiting --> Completed | Trial completion date: Feb 2021 --> Feb 2020 Trial completion date: Jan 2020 --> Nov 2020 | Trial primary completion date: Jan 2020 --> Nov 2020
- | Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial termination: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Jul 13, 2020
P1b/2, N=25, Terminated, Sponsor: Eisai Inc.
Trial completion date: Jan 2020 --> Nov 2020 | Trial primary completion date: Jan 2020 --> Nov 2020 N=14 --> 25 | Active, not recruiting --> Terminated; evolving standard of care and difficulties of enrolling participants
- |||| ipatasertib (RG7440) / Roche
New P2a trial, Combination therapy, Metastases: PATHFINDER: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Jul 8, 2020
P2a, N=54, Not yet recruiting, Sponsor: MedSIR
- || Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jul 8, 2020
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
N=14 --> 25 | Active, not recruiting --> Terminated; evolving standard of care and difficulties of enrolling participants Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: E-SPEC: Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer (clinicaltrials.gov) - Jun 17, 2020
P=N/A, N=120, Active, not recruiting, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023 Trial completion date: Mar 2020 --> Jul 2020 | Trial primary completion date: Mar 2020 --> Jul 2020
- || Halaven (eribulin mesylate) / Eisai, rebastinib (DCC-2036) / Ono Pharma
Trial completion date, Trial primary completion date: Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (clinicaltrials.gov) - Jun 4, 2020
P1, N=60, Recruiting, Sponsor: Montefiore Medical Center
Trial completion date: Mar 2020 --> Jul 2020 | Trial primary completion date: Mar 2020 --> Jul 2020 Trial completion date: Jul 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
- ||| paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial primary completion date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - May 26, 2020
P3, N=150, Not yet recruiting, Sponsor: Angiochem Inc
Trial completion date: Jul 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Jul 2021 Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Jun 2022
- | Halaven (eribulin mesylate) / Eisai
Trial completion: AOST1322: Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - May 19, 2020
P2, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Jun 2022 Active, not recruiting --> Completed
- ||| Halaven (eribulin mesylate) / Eisai, Turalio (pexidartinib) / Daiichi Sankyo
Trial completion, Trial completion date, Metastases: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - May 14, 2020
P1/2, N=67, Completed, Sponsor: Hope Rugo, MD
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2019
- |||||||||| Saituo (trastuzumab biosimilar) / Sino Biopharm, Shenzhen Kexing Pharma
New P3 trial: TQB211-III-01: A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC. (clinicaltrials.gov) - May 12, 2020
P3, N=338, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- || Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 6, 2020
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2019 Trial completion date: Jun 2022 --> May 2023 | Trial primary completion date: Jun 2022 --> May 2023
- | Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: ERIBRAIN: Eribulin in Brain Metastases From HER2-negative Breast Cancer (clinicaltrials.gov) - May 6, 2020
P2, N=0, Withdrawn, Sponsor: Institut Paoli-Calmettes
Trial completion date: Jun 2022 --> May 2023 | Trial primary completion date: Jun 2022 --> May 2023 N=95 --> 0 | Trial completion date: Mar 2024 --> Apr 2020 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2024 --> Apr 2020
- |||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment open: TROPiCS-02: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - May 6, 2020
P3, N=400, Recruiting, Sponsor: Immunomedics, Inc.
N=95 --> 0 | Trial completion date: Mar 2024 --> Apr 2020 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2024 --> Apr 2020 Suspended --> Recruiting
- |||| Margenza (margetuximab-cmkb) / MacroGenics
Trial completion date, Trial primary completion date: SOPHIA: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - May 4, 2020
P3, N=624, Active, not recruiting, Sponsor: MacroGenics
Suspended --> Recruiting Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Dec 2021
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
New P1/2 trial: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Apr 14, 2020
P1/2, N=106, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Apr 10, 2020
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Dec 2021 Trial completion date: Aug 2021 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Jun 2022
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Combination therapy, Metastases: A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients (clinicaltrials.gov) - Apr 10, 2020
P1, N=19, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Aug 2021 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Jun 2022 Trial completion date: Apr 2020 --> Dec 2020
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed, Trial completion date: AOST1322: Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Apr 3, 2020
P2, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2020 --> Dec 2020 Completed --> Active, not recruiting | Trial completion date: Jul 2015 --> Mar 2020